Tempest Therapeutics - TPST Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tempest Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TPST shares.
View TPST analyst ratings or view top-rated stocks.

4 brokers have issued 12 month target prices for Tempest Therapeutics' stock. Their TPST share price forecasts range from $6.00 to $35.00. On average, they anticipate the company's share price to reach $16.33 in the next twelve months. This suggests a possible upside of 1,075.1% from the stock's current price.
View analysts price targets for TPST or view top-rated stocks among Wall Street analysts.

Tempest Therapeutics' stock was trading at $1.15 at the start of the year. Since then, TPST shares have increased by 20.9% and is now trading at $1.39.
View the best growth stocks for 2023 here.

Tempest Therapeutics saw a increase in short interest in February. As of February 28th, there was short interest totaling 16,500 shares, an increase of 17.9% from the February 13th total of 14,000 shares. Based on an average daily volume of 16,100 shares, the short-interest ratio is currently 1.0 days. Approximately 0.4% of the company's stock are short sold.
View Tempest Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Friday, May 12th 2023.
View our TPST earnings forecast.

Tempest Therapeutics, Inc. (NASDAQ:TPST) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($1.21) earnings per share for the quarter, missing analysts' consensus estimates of ($1.05) by $0.16.

Shares of Tempest Therapeutics reverse split on Friday, June 25th 2021. The 1-15 reverse split was announced on Friday, June 25th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 28th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Tempest Therapeutics trades on the NASDAQ under the ticker symbol "TPST."

Tempest Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Thomas W Dubensky and Thomas Woiwode.
View institutional ownership trends.

Shares of TPST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TPST stock can currently be purchased for approximately $1.39.

Tempest Therapeutics (NASDAQ:TPST) has a market capitalization of $14.62 million.

Tempest Therapeutics' mailing address is 110 MILLER AVENUE SUITE 100, ANN ARBOR MI, 48104. The official website for the company is www.millendo.com. The company can be reached via phone at (415) 798-8589 or via email at stephanie@sternir.com.